Immunohistochemically, the CA 19-9 antigen (Koprowski et al., 1979) has been demonstrated in various gastrointestinal carcinomas, such as pancreatic and biliary tract cancer, and also in many normal tissues, among others in pancreatic ducts, gallbladder, extra-and intrahepatic bile ducts, but not in hepatocytes (Atkinson et al., 1982; Arends et al., 1983; Haglund et al., 1986a) . The CA 50 antigen has been detected in tissue extracts from various gastrointestinal and non-gastrointestinal epithelial tumours: pancreatic, colorectal, gastric, gall bladder, lung, urinary bladder, and liver cell carcinomas, as well as carcinomas of the breast and uterine cervix (Nilsson et al., 1983) . Benign and malignant pancreatic lesions express CA 50 (Haglund et al., 1986b) , but CA 50 has not been reported in hepatobiliary lesions.
In this work, we have studied the tissue expression of CA 19-9 and CA 50 in hepatocellular carcinomas and intrahepatic cholangiocarcinomas, as well as in normal liver tissue and liver cirrhosis.
Materials and methods

Specimens
The following specimens were studied: 11 hepatocellular carcinomas; ten cholangiocarcinomas of the liver; four samples of liver cirrhosis; and five samples of normal liver tissue. In addition, histologically normal liver tissue was seen in 16 specimens obtained from livers with carcinoma (all cholangiocarcinomas and half of the hepatocellular carcinomas). The samples were formalin-fixed, paraffin-embedded surgical specimens, which had been stored for between 1 
Controls
The following controls were used: (1) A known CA 19-9 and CA 50 positive specimen of pancreatic carcinoma served as positive control in each series. (2) Sialic acid in the sialosylfucosyl-lactotetraose residue was removed with neuraminidase. Sections were incubated with 0.3 U ml-' Vibrio cholerae neuraminidase (1 U ml-') (Behringwerke, Marburg, Germany), diluted with PBS containing 0.9 mM Ca2" and 0.5 mM Mg2+ for 2 h at 37°C to remove sialic acid before incubation with the primary antibodies. Sections incubated with buffer only served as negative controls.
Results
Normal liver
In all five specimens, many large and middle size bile ducts stained for CA 19-9 and CA 50 ( Figure la and (Koprowski et al., 1979; . Both antibodies react with sialosyl-fucosyl-lactotetraose, corresponding to sialylated blood group antigen Lewis' (Magnani et al., 1982; Mansson et al., 1985) . In addition, the C 50 antibody reacts with a least one other carbohydrate structure, the sialosyl-lactotetraose, which lacks the fucose moiety of sialylated Lewis' . Thus, the C 50 antibody does not require the fucosyl moiety of the sugar chain of the Lea structure for binding.
Immunoperoxidase staining has previously been shown to be a reliable method of demonstrating the CA 19-9 and CA 50 antigens in formalin-fixed, paraffin-embedded specimens. The optimal staining result is obtained after enzyme pretreatment (Haglund et al., 1986a,b) Our results show that the CA 19-9 and CA 50 antigens are normal constituents of bile ducts. There was a slightly stronger expression of CA 50, which might reflect the broader reactivity of the C 50 antibody.
Hepatocellular carcinomas and cholangiocarcinomas showed a clear difference in the expression of tumour marker antigens CA 19-9 and CA 50. Tumour cells of hepatocellular carcinomas did not express these antigens at all. On the other hand, most cholangiocarcinomas (80-90%) stained for both CA 19-9 and CA 50. The staining pattern was similar to that of pancreatic carcinomas (Haglund et al., 1986a,b) . Thus it seems, that the difference between hepatocellular carcinoma and cholangiocarcinoma is more pronounced using staining for CA 19-9 or CA 50 than it is with carcinoembryonic antigen (CEA) or alpha-foetoprotein (AFP). CEA can be found in both cholangiocarcinomas and hepatocellular carcinomas (Kojiro et al., 1981; Goodman et al., 1985) . Alphafoetoprotein is expressed in 35-73% of hepatocellular carcinomas, but not in cholangiocarcinomas (Thung et al., 1979; Kojiro et al., 1981; Goodman et al., 1985) .
Most cholangiocarcinomas show immunohistochemical reactivity for CA 19-9 and CA 50. This is in concordance with the expression of these antigens in serum. Elevated serum levels of CA 19-9 (67-73%) and CA 50 (58%) are frequently seen in patients with bile duct carcinomas (Jalanko et al., 1984; Ritts et al., 1984; Kuusela et al., 1987) . Hepatocellular carcinomas do not stain for either marker. Yet, some patients with hepatocellular carcinoma have elevated CA 19-9 (22%) and CA 50 levels (54-78%) in serum (Jalanko et al., 1984; Chan et al., 1985; Habib et al., 1986; Kuusela et al., 1987 ). An explanation for elevated CA 50 and CA 19-9 levels in serum of patients with hepatocellular carcinomas might be that CA 50 and CA 19-9 is produced by the tumour, but that the serum levels are more sensitive than immunohistochemical staining. However, previous works on pancreatic cancer speak against that theory, as some patients with pancreatic cancer had a strong tissue expression of CA 19-9 and CA 50, but normal serum levels (Haglund et al., 1986a,b) . Furthermore, the percentage of positive serum samples in patients with hepatocellular carcinomas is not greater than the percentage of positive samples in patients with benign liver diseases (Jalanko et al., 1984; Chan et al., 1985; Haglund et al., 1987; Kuusela et al., 1987) . Therefore, we do not think that hepatocellular carcinomas produce neither CA 19-9 nor CA 50.
The reason for the higher frequency of elevated CA 50 than CA 19-9 serum values in liver cirrhosis is not known. Immunohistochemically, both CA 50 and CA 19-9 were strongly and widely expressed, and no difference between these markers could be demonstrated. The C 50 antibody reacts, in addition to sialylated Lewisa with at least one other antigenic determinant, sialosyllactotetraose . This carbohydrate structure could be shed into the blood stream and explain the difference between the expression of the markers.
The reactivity for CA 19-9 and CA 50 in cholangiocarcinomas may be of importance in the differential diagnosis with hepatocellular carcinoma. On the other hand, cholangiocarcinomas of the liver cannot be distinguished from metastatic liver disease. Other gastrointestinal tumours, such as pancreatic, extrahepatic bile duct, gastric and colorectal carcinomas often express CA 19-9 and CA 50 (Atkinson et al., 1982; Arends et al., 1983; Nilsson et al., 1983; Haglund et al., 1 986a,b) , and primary tumours of these organs must be excluded by other diagnostic methods.
